Sequence Variability is Correlated with Weak Immunogenicity in Streptococcus Pyogenes M Protein

Overview

Journal Microbiologyopen

Specialty Microbiology

Date 2015 Jul 16

PMID 26175306

Citations 9

Authors

Jonas Lannergard

Bodil M Kristensen

Mattias C U Gustafsson

Jenny J Persson

Anna Norrby-Teglund

Margaretha Stalhammar-Carlemalm

Gunnar Lindahl

Affiliations

Soon will be listed here.

Abstract

The M protein of Streptococcus pyogenes, a major bacterial virulence factor, has an amino-terminal hypervariable region (HVR) that is a target for type-specific protective antibodies. Intriguingly, the HVR elicits a weak antibody response, indicating that it escapes host immunity by two mechanisms, sequence variability and weak immunogenicity. However, the properties influencing the immunogenicity of regions in an M protein remain poorly understood. Here, we studied the antibody response to different regions of the classical M1 and M5 proteins, in which not only the HVR but also the adjacent fibrinogen-binding B repeat region exhibits extensive sequence divergence. Analysis of antisera from S. pyogenes-infected patients, infected mice, and immunized mice showed that both the HVR and the B repeat region elicited weak antibody responses, while the conserved carboxy-terminal part was immunodominant. Thus, we identified a correlation between sequence variability and weak immunogenicity for M protein regions. A potential explanation for the weak immunogenicity was provided by the demonstration that protease digestion selectively eliminated the HVR-B part from whole M protein-expressing bacteria. These data support a coherent model, in which the entire variable HVR-B part evades antibody attack, not only by sequence variability but also by weak immunogenicity resulting from protease attack.

Citing Articles

Recombinant BL21 with LngA Variants from ETEC E9034A Promotes Adherence to HT-29 Cells.

Espinosa-Mazariego K, Saldana-Ahuactzi Z, Ochoa S, Gonzalez-Pedrajo B, Cevallos M, Rodriguez-Martinez R Pathogens. 2023; 12(2).

PMID: 36839609 PMC: 9962868. DOI: 10.3390/pathogens12020337.

Group A streptococci induce stronger M protein-fibronectin interaction when specific human antibodies are bound.

Wrighton S, Kumra Ahnlide V, Andre O, Bahnan W, Nordenfelt P Front Microbiol. 2023; 14:1069789.

PMID: 36778879 PMC: 9909010. DOI: 10.3389/fmicb.2023.1069789.

A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function.

Bahnan W, Happonen L, Khakzad H, Kumra Ahnlide V, de Neergaard T, Wrighton S EMBO Mol Med. 2022; 15(2):e16208.

PMID: 36507602 PMC: 9906385. DOI: 10.15252/emmm.202216208.

Analysis of lineage-specific protein family variability in prokaryotes combined with evolutionary reconstructions.

Karamycheva S, Wolf Y, Persi E, Koonin E, Makarova K Biol Direct. 2022; 17(1):22.

PMID: 36042479 PMC: 9425974. DOI: 10.1186/s13062-022-00337-7.

Structural determination of Streptococcus pyogenes M1 protein interactions with human immunoglobulin G using integrative structural biology.

Khakzad H, Happonen L, Karami Y, Chowdhury S, Erturk Bergdahl G, Nilges M PLoS Comput Biol. 2021; 17(1):e1008169.

PMID: 33411763 PMC: 7817036. DOI: 10.1371/journal.pcbi.1008169.

References

Sandin C, Carlsson F, Lindahl G . Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes. Mol Microbiol. 2005; 59(1):20-30. DOI: 10.1111/j.1365-2958.2005.04913.x. View

Becker S, Frankel M, Schneewind O, Missiakas D . Release of protein A from the cell wall of Staphylococcus aureus. Proc Natl Acad Sci U S A. 2014; 111(4):1574-9. PMC: 3910568. DOI: 10.1073/pnas.1317181111. View

Larsson C, Stalhammar-Carlemalm M, Lindahl G . Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Infect Immun. 1996; 64(9):3518-23. PMC: 174257. DOI: 10.1128/iai.64.9.3518-3523.1996. View

Frelinger 3rd A, Cohen I, Plow E, Smith M, Roberts J, Lam S . Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem. 1990; 265(11):6346-52. View

Sanderson-Smith M, De Oliveira D, Guglielmini J, McMillan D, Vu T, Holien J . A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. J Infect Dis. 2014; 210(8):1325-38. PMC: 6083926. DOI: 10.1093/infdis/jiu260. View

Lancefield R . Persistence of type-specific antibodies in man following infection with group A streptococci. J Exp Med. 1959; 110(2):271-92. PMC: 2136986. DOI: 10.1084/jem.110.2.271. View

Takahashi I, Nochi T, Yuki Y, Kiyono H . New horizon of mucosal immunity and vaccines. Curr Opin Immunol. 2009; 21(3):352-8. DOI: 10.1016/j.coi.2009.04.002. View

Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, Norrby-Teglund A . M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell. 2004; 116(3):367-79. DOI: 10.1016/s0092-8674(04)00057-1. View

Ferretti J, McShan W, Ajdic D, Savic D, Savic G, Lyon K . Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc Natl Acad Sci U S A. 2001; 98(8):4658-63. PMC: 31890. DOI: 10.1073/pnas.071559398. View

10.

DENNY Jr F, PERRY W, Wannamaker L . Type-specific streptococcal antibody. J Clin Invest. 1957; 36(7):1092-100. PMC: 1072695. DOI: 10.1172/JCI103504. View

11.

Aziz R, Pabst M, Jeng A, Kansal R, Low D, Nizet V . Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. Mol Microbiol. 2003; 51(1):123-34. DOI: 10.1046/j.1365-2958.2003.03797.x. View

12.

Carapetis J, Steer A, Mulholland E, Weber M . The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005; 5(11):685-94. DOI: 10.1016/S1473-3099(05)70267-X. View

13.

McMillan D, Dreze P, Vu T, Bessen D, Guglielmini J, Steer A . Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clin Microbiol Infect. 2013; 19(5):E222-9. PMC: 4568957. DOI: 10.1111/1469-0691.12134. View

14.

Sun H, Ringdahl U, Homeister J, Fay W, Engleberg N, Yang A . Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science. 2004; 305(5688):1283-6. DOI: 10.1126/science.1101245. View

15.

Akerstrom B, Lindahl G, Bjorck L, Lindqvist A . Protein Arp and protein H from group A streptococci. Ig binding and dimerization are regulated by temperature. J Immunol. 1992; 148(10):3238-43. View

16.

Daikos G, WEINSTEIN L . Streptococcal bacteriostatic antibody in patients treated with penicillin. Proc Soc Exp Biol Med. 1951; 78(1):160-3. DOI: 10.3181/00379727-78-19007. View

17.

Miller L, Gray L, Beachey E, Kehoe M . Antigenic variation among group A streptococcal M proteins. Nucleotide sequence of the serotype 5 M protein gene and its relationship with genes encoding types 6 and 24 M proteins. J Biol Chem. 1988; 263(12):5668-73. View

18.

Connolly K, Roberts A, Holder R, Reid S . Dispersal of Group A streptococcal biofilms by the cysteine protease SpeB leads to increased disease severity in a murine model. PLoS One. 2011; 6(4):e18984. PMC: 3081844. DOI: 10.1371/journal.pone.0018984. View

19.

Nelson D, Garbe J, Collin M . Cysteine proteinase SpeB from Streptococcus pyogenes - a potent modifier of immunologically important host and bacterial proteins. Biol Chem. 2011; 392(12):1077-88. DOI: 10.1515/BC.2011.208. View

20.

Speziale P, Joh D, Visai L, Bozzini S, Lindberg M, Hook M . A monoclonal antibody enhances ligand binding of fibronectin MSCRAMM (adhesin) from Streptococcus dysgalactiae. J Biol Chem. 1996; 271(3):1371-8. DOI: 10.1074/jbc.271.3.1371. View